Background: The aim of this study is to investigate the role of Galectin-3 in human thyroid cancer migration.

Methods: The expression of Galectin-3 in surgical specimens was investigated using immunohistochemistry and western blot. A papillary thyroid cancer cell line (B-cpap) and an anaplastic thyroid cancer cell line (8305c) were transfected with short-hairpin RNA against Galectin-3 (Gal-3-shRNA). Low-molecular citrus pectin (LCP) was also used to antagonize Galectin-3. The migration and invasion of the cell lines were examined. The related signaling pathways were investigated to explore the Galectin-3 mechanism of action.

Results: Galectin-3 was highly expressed in metastasized thyroid cancers. Knocking down and antagonizing Galectin-3 significantly suppressed the migration of thyroid cancer cells. Knocking down Galectin-3 inhibited the activity of Wnt, MAPK, Src and Rho signaling pathways. Galectin-3 was up-regulated via HIF-1α in a hypoxic environment. Galectin-3 knockdown could reduce cell motility in hypoxic environments.

Conclusion: This study suggests that Galectin-3 could act as a modulator of thyroid cancer migration, especially in hypoxic microenvironments. This regulation function of Galectin-3 may work through multiple signaling pathways.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731889PMC
http://dx.doi.org/10.18632/oncotarget.21135DOI Listing

Publication Analysis

Top Keywords

thyroid cancer
24
galectin-3
13
signaling pathways
12
migration thyroid
8
cancer cells
8
cancer cell
8
thyroid
7
cancer
6
cell
5
galectin-3 induced
4

Similar Publications

In this study, we identified cancer-associated fibroblast (CAF) molecular subtypes and developed a CAF-based prognostic model for breast cancer (BRCA). The heterogeneity of cancer-associated fibroblasts (CAFs) and their significant involvement in the advancement of BRCA were discovered employing single-cell RNA sequencing. Notably, we discovered that the RUNX1/SDC1 axis enhances BRCA cell invasion and metastasis.

View Article and Find Full Text PDF

Thyroid surgery under nerve auto-fluorescence & artificial intelligence tissue identification software guidance.

Langenbecks Arch Surg

January 2025

Department of General Surgery, Sanatorio Otamendi & Miroli (Otamendi & Miroli Hospital), University of Buenos Aires, Buenos Aires, Argentina.

Thyroid cancer is a common malignancy that requires comprehensive clinical evaluation prior to adequate surgical management. Over the last three decades thyroid surgery has tripled and is considered one of the most commonly performed procedures in general surgery. These procedures are associated with potential postoperative complications with significant deterioration in the patient's quality of life.

View Article and Find Full Text PDF

Comprehensive analysis of clinicopathologic and prognostic features in locally advanced thyroid papillary cancer.

Braz J Otorhinolaryngol

January 2025

Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Department of Head and Neck Surgery, Liaoning Province, China.

Objective: Differentiated thyroid cancers tend to excellent long-term survival after surgery. However, Locally Advanced Papillary Thyroid Cancers (LAPTCs) have poor prognosis. This study was to investigate the clinicopathologic features of LAPTC and the risk factors that affect its postoperative recurrence.

View Article and Find Full Text PDF

Autism spectrum disorder (ASD) is a pervasive neurobehavioral condition characterized by disruption of behavioral and emotional patterns in individuals with this condition. Given that various environmental and genetic factors play a fundamental role in the pathophysiology of ASD, it can be said that ASD is a multifaceted disease. This study used scientific databases including Google Scholar, PubMed, Scopus, and Semantic Scholar.

View Article and Find Full Text PDF

Background: Few studies have examined childbirth and adverse perinatal outcomes among male adolescents and young adults with cancer (AYAs, diagnosed at age 15-39 years). We conducted a population-based assessment of these outcomes in a large, diverse sample.

Methods: Male AYAs diagnosed between January 1, 1995 and December 31, 2015 were identified using the Texas Cancer Registry and linked to live birth certificates and the Texas Birth Defects Registry through December 31, 2016.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!